Effects of adjuvants in a rabies-vectored Ebola virus vaccine on protection from surrogate challenge
Abstract Ebola virus is the primary contributor to the global threat of filovirus severe hemorrhagic fever, and Ebola virus disease has a case fatality rate of 50–90%. An inactivated, bivalent filovirus/rabies virus vaccine, FILORAB1, consists of recombinant rabies virus virions expressing the Ebola...
保存先:
| 主要な著者: | , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Nature Portfolio
2023-02-01
|
| シリーズ: | npj Vaccines |
| オンライン･アクセス: | https://doi.org/10.1038/s41541-023-00615-z |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|